Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism

Del D. Miller, Vicki L. Ellingrod, Timothy L. Holman, Peter F Buckley, Stephan Arndt

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Weight gain has been documented as a significant adverse effect associated with many of the atypical antipsychotic medications. Several recent reports have linked a -759C/T polymorphism of the 5HT2C receptor gene and obesity as well as chlorpromazine, risperidone, and clozapine induced to weight gain. This aim was to determine the association between changes in body mass index (BMI) during clozapine treatment and the -759C/ T polymorphism of the 5HT2C receptor gene. This study included 41 patients with treatment-refractory schizophrenia (DSM-IV) who were followed prospectively during treatment with clozapine. Weight and height measurements were obtained prior to starting clozapine and after 6-months of treatment. Genomic DNA was isolated from a whole blood sample and analyzed for the -759C/ T polymorphism of the 5HT2C receptor gene. A χ2 analysis comparing whether or not the subjects carried a -759T allele in subjects grouped as having an increase of more or less than 7% of their baseline BMI during treatment with clozapine found that the presence of the -759T allele was significantly higher in subjects with less than or equal to a 7% increase in baseline BMI compared to those with a greater than 7% increase in BMI. A multiple linear regression analysis showed that both baseline BMI and the presence or absence of the -759T allele had significant effects on 6-month BMI. The T allele may have a protective function in preventing significant weight gain from clozapine. Subjects without the -759T variant allele were at a greater risk for weight gain from clozapine over 6-months compared to those with the -759T allele.

Original languageEnglish (US)
Pages (from-to)97-100
Number of pages4
JournalAmerican Journal of Medical Genetics - Neuropsychiatric Genetics
Volume133 B
Issue number1
DOIs
StatePublished - Feb 5 2005

Fingerprint

Clozapine
Weight Gain
Body Mass Index
Alleles
Genes
Therapeutics
Risperidone
Chlorpromazine
Diagnostic and Statistical Manual of Mental Disorders
Antipsychotic Agents
Linear Models
Schizophrenia
Obesity
Regression Analysis
Weights and Measures
DNA

Keywords

  • 5HT2C receptor
  • Body mass index
  • Clozapine
  • Weight gain

ASJC Scopus subject areas

  • Genetics(clinical)
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. / Miller, Del D.; Ellingrod, Vicki L.; Holman, Timothy L.; Buckley, Peter F; Arndt, Stephan.

In: American Journal of Medical Genetics - Neuropsychiatric Genetics, Vol. 133 B, No. 1, 05.02.2005, p. 97-100.

Research output: Contribution to journalArticle

Miller, Del D. ; Ellingrod, Vicki L. ; Holman, Timothy L. ; Buckley, Peter F ; Arndt, Stephan. / Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. In: American Journal of Medical Genetics - Neuropsychiatric Genetics. 2005 ; Vol. 133 B, No. 1. pp. 97-100.
@article{f05f210f66934c6eb0d70a203e1bd358,
title = "Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism",
abstract = "Weight gain has been documented as a significant adverse effect associated with many of the atypical antipsychotic medications. Several recent reports have linked a -759C/T polymorphism of the 5HT2C receptor gene and obesity as well as chlorpromazine, risperidone, and clozapine induced to weight gain. This aim was to determine the association between changes in body mass index (BMI) during clozapine treatment and the -759C/ T polymorphism of the 5HT2C receptor gene. This study included 41 patients with treatment-refractory schizophrenia (DSM-IV) who were followed prospectively during treatment with clozapine. Weight and height measurements were obtained prior to starting clozapine and after 6-months of treatment. Genomic DNA was isolated from a whole blood sample and analyzed for the -759C/ T polymorphism of the 5HT2C receptor gene. A χ2 analysis comparing whether or not the subjects carried a -759T allele in subjects grouped as having an increase of more or less than 7{\%} of their baseline BMI during treatment with clozapine found that the presence of the -759T allele was significantly higher in subjects with less than or equal to a 7{\%} increase in baseline BMI compared to those with a greater than 7{\%} increase in BMI. A multiple linear regression analysis showed that both baseline BMI and the presence or absence of the -759T allele had significant effects on 6-month BMI. The T allele may have a protective function in preventing significant weight gain from clozapine. Subjects without the -759T variant allele were at a greater risk for weight gain from clozapine over 6-months compared to those with the -759T allele.",
keywords = "5HT2C receptor, Body mass index, Clozapine, Weight gain",
author = "Miller, {Del D.} and Ellingrod, {Vicki L.} and Holman, {Timothy L.} and Buckley, {Peter F} and Stephan Arndt",
year = "2005",
month = "2",
day = "5",
doi = "10.1002/ajmg.b.30115",
language = "English (US)",
volume = "133 B",
pages = "97--100",
journal = "American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics",
issn = "1552-4841",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism

AU - Miller, Del D.

AU - Ellingrod, Vicki L.

AU - Holman, Timothy L.

AU - Buckley, Peter F

AU - Arndt, Stephan

PY - 2005/2/5

Y1 - 2005/2/5

N2 - Weight gain has been documented as a significant adverse effect associated with many of the atypical antipsychotic medications. Several recent reports have linked a -759C/T polymorphism of the 5HT2C receptor gene and obesity as well as chlorpromazine, risperidone, and clozapine induced to weight gain. This aim was to determine the association between changes in body mass index (BMI) during clozapine treatment and the -759C/ T polymorphism of the 5HT2C receptor gene. This study included 41 patients with treatment-refractory schizophrenia (DSM-IV) who were followed prospectively during treatment with clozapine. Weight and height measurements were obtained prior to starting clozapine and after 6-months of treatment. Genomic DNA was isolated from a whole blood sample and analyzed for the -759C/ T polymorphism of the 5HT2C receptor gene. A χ2 analysis comparing whether or not the subjects carried a -759T allele in subjects grouped as having an increase of more or less than 7% of their baseline BMI during treatment with clozapine found that the presence of the -759T allele was significantly higher in subjects with less than or equal to a 7% increase in baseline BMI compared to those with a greater than 7% increase in BMI. A multiple linear regression analysis showed that both baseline BMI and the presence or absence of the -759T allele had significant effects on 6-month BMI. The T allele may have a protective function in preventing significant weight gain from clozapine. Subjects without the -759T variant allele were at a greater risk for weight gain from clozapine over 6-months compared to those with the -759T allele.

AB - Weight gain has been documented as a significant adverse effect associated with many of the atypical antipsychotic medications. Several recent reports have linked a -759C/T polymorphism of the 5HT2C receptor gene and obesity as well as chlorpromazine, risperidone, and clozapine induced to weight gain. This aim was to determine the association between changes in body mass index (BMI) during clozapine treatment and the -759C/ T polymorphism of the 5HT2C receptor gene. This study included 41 patients with treatment-refractory schizophrenia (DSM-IV) who were followed prospectively during treatment with clozapine. Weight and height measurements were obtained prior to starting clozapine and after 6-months of treatment. Genomic DNA was isolated from a whole blood sample and analyzed for the -759C/ T polymorphism of the 5HT2C receptor gene. A χ2 analysis comparing whether or not the subjects carried a -759T allele in subjects grouped as having an increase of more or less than 7% of their baseline BMI during treatment with clozapine found that the presence of the -759T allele was significantly higher in subjects with less than or equal to a 7% increase in baseline BMI compared to those with a greater than 7% increase in BMI. A multiple linear regression analysis showed that both baseline BMI and the presence or absence of the -759T allele had significant effects on 6-month BMI. The T allele may have a protective function in preventing significant weight gain from clozapine. Subjects without the -759T variant allele were at a greater risk for weight gain from clozapine over 6-months compared to those with the -759T allele.

KW - 5HT2C receptor

KW - Body mass index

KW - Clozapine

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=12944265464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944265464&partnerID=8YFLogxK

U2 - 10.1002/ajmg.b.30115

DO - 10.1002/ajmg.b.30115

M3 - Article

VL - 133 B

SP - 97

EP - 100

JO - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

JF - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

SN - 1552-4841

IS - 1

ER -